A Look at Brainstorm Cell Therapeutics Inc. (BCLI) Shares in the Recent Past Indicates Growth

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) stock jumped 3.17% on Monday to $0.99 against a previous-day closing price of $0.96. With 0.53 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.27 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.0600 whereas the lowest price it dropped to was $0.9600. The 52-week range on BCLI shows that it touched its highest point at $4.56 and its lowest point at $0.95 during that stretch. It currently has a 1-year price target of $15.00. Beta for the stock currently stands at -0.46.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BCLI was down-trending over the past week, with a drop of -25.76%, but this was down by -33.23% over a month. Three-month performance dropped to -62.03% while six-month performance fell -38.21%. The stock lost -76.87% in the past year, while it has lost -39.34% so far this year. A look at the trailing 12-month EPS for BCLI yields -0.60 with Next year EPS estimates of -0.50. For the next quarter, that number is -0.14. This implies an EPS growth rate of 1.60% for this year and 28.60% for next year.

Float and Shares Shorts:

At present, 39.70 million BCLI shares are outstanding with a float of 35.79 million shares on hand for trading. On Aug 30, 2023, short shares totaled 3.22 million, which was 7.15% higher than short shares on Jul 30, 2023. In addition to Mr. Chaim Lebovits as the firm’s Pres & CEO, Dr. Stacy R. Lindborg Ph.D. serves as its Co-Chief Exec. Officer.

Institutional Ownership:

Through their ownership of 13.43% of BCLI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.76% of BCLI, in contrast to 4.08% held by mutual funds. Shares owned by individuals account for 12.55%. As the largest shareholder in BCLI with 3.13% of the stake, The Vanguard Group, Inc. holds 1,408,450 shares worth 1,408,450. A second-largest stockholder of BCLI, AIGH Capital Management LLC, holds 708,235 shares, controlling over 1.57% of the firm’s shares. Susquehanna Financial Group LLLP is the third largest shareholder in BCLI, holding 490,109 shares or 1.09% stake. With a 2.11% stake in BCLI, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 951,371 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.89% of BCLI stock, is the second-largest Mutual Fund holder. It holds 401,014 shares valued at 0.69 million. Fidelity Extended Market Index Fu holds 0.33% of the stake in BCLI, owning 149,185 shares worth 0.26 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, BCLI reported revenue of $0.00 and operating income of -$7.59M. The EBITDA in the recently reported quarter was -$7.52M and diluted EPS was -$0.19.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BCLI since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BCLI analysts setting a high price target of $20.00 and a low target of $10.00, the average target price over the next 12 months is $15.00. Based on these targets, BCLI could surge 1920.2% to reach the target high and rise by 910.1% to reach the target low. Reaching the average price target will result in a growth of 1415.15% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded BCLI stock several times over the past three months with 3 Buys and 0 Sells. In these transactions, 78,184 shares were bought while 0 shares were sold. The number of buy transactions has increased to 7 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 298,184 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *